Three-month outcome of ziv-aflibercept for exudative age-related macular degeneration. (Q53134473)

From Wikidata

Jump to navigation Jump to search

scientific article published on 30 March 2016

edit

Language	Label	Description	Also known as
English	Three-month outcome of ziv-aflibercept for exudative age-related macular degeneration.	scientific article published on 30 March 2016

Statements

instance of

scholarly article

1 reference

stated in

Europe PubMed Central

PubMed publication ID

27030277

retrieved

11 May 2018

reference URL

http://europepmc.org/abstract/MED/27030277

title

Three-month outcome of ziv-aflibercept for exudative age-related macular degeneration. (English)

1 reference

stated in

Europe PubMed Central

PubMed publication ID

27030277

retrieved

11 May 2018

reference URL

http://europepmc.org/abstract/MED/27030277

main subject

aflibercept

1 reference

based on heuristic

inferred from title

author name string

Ahmad M Mansour

series ordinal

1

1 reference

stated in

Europe PubMed Central

PubMed publication ID

27030277

retrieved

11 May 2018

reference URL

http://europepmc.org/abstract/MED/27030277

Jay Chhablani

series ordinal

2

1 reference

stated in

Europe PubMed Central

PubMed publication ID

27030277

retrieved

11 May 2018

reference URL

http://europepmc.org/abstract/MED/27030277

Rafic S Antonios

series ordinal

3

1 reference

stated in

Europe PubMed Central

PubMed publication ID

27030277

retrieved

11 May 2018

reference URL

http://europepmc.org/abstract/MED/27030277

Rohit Yogi

series ordinal

4

1 reference

stated in

Europe PubMed Central

PubMed publication ID

27030277

retrieved

11 May 2018

reference URL

http://europepmc.org/abstract/MED/27030277

Muhammad H Younis

series ordinal

5

1 reference

stated in

Europe PubMed Central

PubMed publication ID

27030277

retrieved

11 May 2018

reference URL

http://europepmc.org/abstract/MED/27030277

Rola Dakroub

series ordinal

6

1 reference

stated in

Europe PubMed Central

PubMed publication ID

27030277

retrieved

11 May 2018

reference URL

http://europepmc.org/abstract/MED/27030277

Hasan Chahine

series ordinal

7

1 reference

stated in

Europe PubMed Central

PubMed publication ID

27030277

retrieved

11 May 2018

reference URL

http://europepmc.org/abstract/MED/27030277

language of work or name

English

0 references

publication date

30 March 2016

1 reference

stated in

Europe PubMed Central

PubMed publication ID

27030277

retrieved

11 May 2018

reference URL

http://europepmc.org/abstract/MED/27030277

published in

British Journal of Ophthalmology

1 reference

stated in

Europe PubMed Central

PubMed publication ID

27030277

retrieved

11 May 2018

reference URL

http://europepmc.org/abstract/MED/27030277

volume

100

1 reference

stated in

Europe PubMed Central

PubMed publication ID

27030277

retrieved

11 May 2018

reference URL

http://europepmc.org/abstract/MED/27030277

issue

12

1 reference

stated in

Europe PubMed Central

PubMed publication ID

27030277

retrieved

11 May 2018

reference URL

http://europepmc.org/abstract/MED/27030277

page(s)

1629-1633

1 reference

stated in

Europe PubMed Central

PubMed publication ID

27030277

retrieved

11 May 2018

reference URL

http://europepmc.org/abstract/MED/27030277

cites work

Efficacy and adverse events of aflibercept, ranibizumab and bevacizumab in age-related macular degeneration: a trade-off analysis

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1136%2FBJOPHTHALMOL-2015-308319

retrieved

21 January 2018

Intravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six-week results of the VIEW studies

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1136%2FBJOPHTHALMOL-2015-308319

retrieved

21 January 2018

Ziv-aflibercept: a novel angiogenesis inhibitor for the treatment of metastatic colorectal cancer

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1136%2FBJOPHTHALMOL-2015-308319

retrieved

21 January 2018

Safety profiles of anti-VEGF drugs: bevacizumab, ranibizumab, aflibercept and ziv-aflibercept on human retinal pigment epithelium cells in culture.

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1136%2FBJOPHTHALMOL-2015-308319

retrieved

21 January 2018

Preclinical investigations of intravitreal ziv-aflibercept.

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1136%2FBJOPHTHALMOL-2015-308319

retrieved

21 January 2018

Intravitreal ziv-aflibercept for recurrent macular edema secondary to central retinal venous occlusion

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1136%2FBJOPHTHALMOL-2015-308319

retrieved

21 January 2018

Intravitreal injection of ziv-aflibercept in patient with refractory age-related macular degeneration.

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1136%2FBJOPHTHALMOL-2015-308319

retrieved

21 January 2018

Ziv-aflibercept in macular disease

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1136%2FBJOPHTHALMOL-2015-308319

retrieved

21 January 2018

Delayed treatment initiation of more than 2 weeks. Relevance for possible gain of visual acuity after anti-VEGF therapy under real life conditions (interim analysis of the prospective OCEAN study)

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1136%2FBJOPHTHALMOL-2015-308319

retrieved

21 January 2018

Delay to treatment and visual outcomes in patients treated with anti-vascular endothelial growth factor for age-related macular degeneration

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1136%2FBJOPHTHALMOL-2015-308319

retrieved

21 January 2018

Intravitreal anti-vascular endothelial growth factor for submacular hemorrhage from choroidal neovascularization

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1136%2FBJOPHTHALMOL-2015-308319

retrieved

21 January 2018

Intravitreal anti-VEGF monotherapy for thick submacular hemorrhage of less than 1 week duration secondary to neovascular age-related macular degeneration

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1136%2FBJOPHTHALMOL-2015-308319

retrieved

21 January 2018

Cost-effectiveness of bevacizumab and ranibizumab for newly diagnosed neovascular macular degeneration.

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1136%2FBJOPHTHALMOL-2015-308319

retrieved

21 January 2018

Drugs for macular degeneration, price discrimination, and Medicare’s responsibility not to overpay.

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1136%2FBJOPHTHALMOL-2015-308319

retrieved

21 January 2018

Ranibizumab (Lucentis) versus bevacizumab (Avastin): modelling cost effectiveness

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1136%2FBJOPHTHALMOL-2015-308319

retrieved

21 January 2018

Identifiers

DOI

10.1136/BJOPHTHALMOL-2015-308319

1 reference

stated in

Europe PubMed Central

PubMed publication ID

27030277

retrieved

11 May 2018

reference URL

http://europepmc.org/abstract/MED/27030277

PubMed publication ID

27030277

1 reference

stated in

Europe PubMed Central

PubMed publication ID

27030277

retrieved

11 May 2018

reference URL

http://europepmc.org/abstract/MED/27030277

 

Sitelinks

Wikipedia(0 entries)

edit

Wikibooks(0 entries)

edit

Wikinews(0 entries)

edit

Wikiquote(0 entries)

edit

Wikisource(0 entries)

edit

Wikiversity(0 entries)

edit

Wikivoyage(0 entries)

edit

Wiktionary(0 entries)

edit

Multilingual sites(0 entries)

edit

Retrieved from "https://www.wikidata.org/w/index.php?title=Q53134473&oldid=1508999975"